Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Genetically Engineered Cells (iC9-CAR.B7-H3 T cells) for the Treatment of Patients with Relapsed or Refractory Triple Negative Breast Cancer

Trial Status: active

This phase I trial tests the safety, side effects, and best dose of iC9-CAR.B7-H3 T cells in treating patients with triple negative breast cancer (TNBC) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Chimeric antigen receptor (CAR) T cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving iC9-CAR.B7-H3 T cells may be safe, tolerable, and/or effective in treating patients with TNBC.